Credit Suisse Ag Shattuck Labs, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.7 - $4.59 $30,339 - $51,577	-11,237 Reduced 99.88%	14 $0
Q1 2022 May 16, 2022	BUY	$4.22 - $8.89 $2,384 - $5,022	565 Added 5.29%	11,251 $48,000
Q4 2021 Feb 14, 2022	BUY	$8.36 - $21.08 $6,721 - $16,948	804 Added 8.14%	10,686 $91,000
Q3 2021 Nov 12, 2021	SELL	$17.57 - $28.95 $9,013 - $14,851	-513 Reduced 4.94%	9,882 $202,000
Q2 2021 Aug 16, 2021	BUY	$24.14 - $37.68 $250,935 - $391,683	10,395 New	10,395 $301,000
Q1 2021 May 14, 2021	SELL	$27.92 - $52.5 $111,596 - $209,842	-3,997 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$19.0 - $57.61 $75,943 - $230,267	3,997 New	3,997 $209,000

28.8M

300

1.2K

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $46.6M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.